Tevogen Bio Stock (NASDAQ:TVGN)


OwnershipFinancialsChart

Previous Close

$1.33

52W Range

$0.26 - $21.09

50D Avg

$1.14

200D Avg

$2.02

Market Cap

$232.08M

Avg Vol (3M)

$15.65M

Beta

-1.03

Div Yield

-

TVGN Company Profile


Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

17

IPO Date

Jan 05, 2022

Website

TVGN Performance


TVGN Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-2.27M$-13.72M$-4.62M
Net Income$-67.33K$4.41M$-15.60M
EBITDA$-2.27M$-953.08K$-14.99M
Basic EPS-$0.04$-0.13
Diluted EPS-$0.04$-0.13

Fiscal year ends in Dec 23 | Currency in USD